Piotr Machowiec

Mr. Piotr Machowiec

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
PMPiotr Machowiec
Piotr Machowiec
GRGabriela Ręka
Gabriela Ręka
MMMarcela Maksymowicz
Marcela Maksymowicz
HPHalina Piecewicz-Szczęsna
Halina Piecewicz-Szczęsna
ASAgata Smoleń
Agata Smoleń
Spirulina is a microalga that presents various important pro-health properties, for instance lowering blood pressure in the research. The study aims to appraise the efficacy of Spirulina administration on systolic (SBP) and diastolic blood pressure (DBP). Randomized controlled trials (RCTs) were retrieved by a systematic search of PubMed, Web of Science, and the Cochrane Library databases from inception to June 2021 according to a standardized protocol. The effect size of each study was counted from mean and standard deviation before and after the intervention and shown as Un-standardized mean difference and 95% confidence interval. Sensitivity analyses were performed. Meta-analysis on 5 RCTs with 230 subjects was eligible. The amount of Spirulina ranged from 1 to 8 g per day, and intervention durations ranged from 2 to 12 weeks. Data analysis indicated that Spirulina supplementation led to a significant lowering of SBP (Mean Difference (MD): −4.59 mmHg, 95% Confidence Interval (CI): −8.20 to −0.99, I square statistic (I2) = 65%) and significant lowering of DBP (MD: −7.02 mmHg, CI: −8.86 to −5.18, I2 = 11%), particularly in a subgroup of hypertensive patients. Spirulina administration might have a supportive effect on the prevention and treatment of hypertension. More exact randomized controlled trials are needed to clarify the effect of Spirulina supplementation on blood pressure.

7 November 2021 in Medicina
Verified
Journal Article
Open access
PDF file
ZPZuzanna Pelc
Zuzanna Pelc
MSMagdalena Skórzewska
Magdalena Skórzewska
AKAndrzej Kurylcio
Andrzej Kurylcio
POPaweł Olko
Paweł Olko
JDJoanna Dryka
Joanna Dryka
Wojciech PolkowskiWojciech Polkowski
Wojciech Polkowski
Breast implantation (BI) is the most common plastic surgery worldwide performed among women. Generally, BI is performed both in aesthetic and oncoplastic procedures. Recently, the prevalence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) or breast implant illness (BII) has aroused concerns. As a result, several countries, like Australia, Korea or the United Kingdom, introduced national registries dedicated to the safety and quality of BI surgeries. This narrative review aimed to focus on the clinical challenges, management and the current state of knowledge of BI. Both short and long-term outcomes of BI are determined by various alternatives and differences, which surgeons must consider during the planning and performing breast augmentation along with further complications or risk of reoperation. Proper preoperative decisions and aspects of surgical technique emerged to be equally important. The number of performed breast reconstructions is increasing, providing the finest aesthetic results and improving patient’s quality of life. Choice of prosthesis varies according to individual preferences and anatomical variables. A newly diagnosed cases of BIA-ALCL with lacking data on prevention, diagnosis, and treatment are placing it as a compelling medical challenge. Similarly, BII remains one of the most controversial subjects in reconstructive breast surgery due to unspecified diagnostic procedures, and recommendations.

29 December 2021 in Journal of Pre-Clinical and Clinical Research
Verified
Journal Article
Open access
MMMarcela Maksymowicz
Marcela Maksymowicz
PMPiotr Machowiec
Piotr Machowiec
GRGabriela Ręka
Gabriela Ręka
AKAnna Korzeniowska
Anna Korzeniowska
PLPatryk Leszczyk
Patryk Leszczyk
HPHalina Piecewicz-Szczęsna
Halina Piecewicz-Szczęsna
Introduction and objective: Triclosan is a synthetic, aromatic organic chemical compound with antimicrobial properties. Due to its wide application as a preservative in cosmetics, antiperspirants, plastics, or surgical sutures, various mechanisms of TCS action on the human body are...

5 June 2023 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MMMarcela Maksymowicz
Marcela Maksymowicz
PMPiotr Machowiec
Piotr Machowiec
AKAnna Korzeniowska
Anna Korzeniowska
NBNatalia Baran
Natalia Baran
ABAdriana Bielak
Adriana Bielak
KBKlaudia Bogusz
Klaudia Bogusz
Introduction and purpose Breast cancer (BC) management includes local therapies surgery, radiotherapy and systemic – hormonotherapy, chemotherapy, targeted and immunotherapy. However, some adverse events of these treatment strategies limit their wide administration in BC therapy. The aim of the study was to present adverse effects in the management of BC, prevention and treatment of them. State of the knowledge Surgery of the breast leads to lymphedema, pain, and anatomical changes. The most characteristic adverse event of radiotherapy is radiation dermatitis which is more probable among obese, older patients, females, and smokers. Other side effects are pneumonia, cardiac and pulmonary injury. Chemotherapeutics lead to complications such as anthracyclines-induced cardiotoxicity. As a consequence of endocrine therapy, patients are affected by vasomotor, musculoskeletal, and vulvovaginal symptoms. Immune checkpoint inhibitors may cause immune-related adverse events (irAEs), which are usually mild. When severe irAEs occur, immunosuppressive drugs are used. Depending on stage, toxicities of the therapies can lead to interrupting the treatment of BC. Moreover, drug resistance is an important therapeutic obstacle in BC treatment. Conclusion The application of a diversity of drugs in the treatment of breast cancer is associated with adverse effects which limit its efficacy. It is vital to develop novel, targeted therapeutic methods to optimize outcomes of patients. Given the adverse effects of breast cancer therapies and drug resistance, it is vital to develop novel, targeted therapeutic methods.

28 December 2021 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
PMPiotr Machowiec
Piotr Machowiec
MMMarcela Maksymowicz
Marcela Maksymowicz
HPHalina Piecewicz-Szczęsna
Halina Piecewicz-Szczęsna
Introduction and objective: The ketogenic diet (KD) is a high-fat, adequate-protein, low-carbohydrate diet that is getting more and more widespread in medicine. This dietary intervention causes changes in cerebral metabolism, which are considered potentially beneficial in patients with...

11 September 2021 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MMMarcela Maksymowicz
Marcela Maksymowicz
PMPiotr Machowiec
Piotr Machowiec
NBNatalia Baran
Natalia Baran
MPMałgorzata Piekarska
Małgorzata Piekarska
Introduction and purposeSoy as a rich source of isoflavones has become a focus of interest because of its positive health benefits on numerous diseases, particularly hormone-related cancers. The aim of this study was to present the current state of knowledge on the role of soy in the development of breast, ovarian, endometrial, and prostate gland cancer.A brief description of the state of knowledgeSoy components reduce inflammation, stress oxidative and inhibit proliferation of breast, ovarian, endometrial, and prostate cancer cells. Isoflavones such as genistein, daidzein, S-equol via activation of estrogen receptors, inhibit aromatase synthesis and may decrease the risk of estrogen-dependent cancers. Moreover, soy food products have the potential toregulate molecular pathways of AR and reduce testosterone levels. It leads to a reduced risk of prostate cancer. Furthermore, increased consumption of soy protein and isoflavones decreased the risk of mortality from cancers.ConclusionsSoy foods and their isoflavones are associated with reduced carcinogenesis. A higher amount of soy intake can have positive benefits for prevention of cancers including breast, prostate gland, endometrial and ovarian cancer.